Table 7 Univariate regression analysis and multivariate regression analysis for PFS.

From: The efficacy and safety analysis of D-TACE combined with donafenib and tislelizumab in recurrent hepatocellular carcinoma after surgery

Characteristics

Univariate regression analysis

Multivariate regression analysis

P value

P value

HR (95%CI)

Group/Treatment

< 0.001

< 0.001

0.323(0.206,0.508)

Gender

0.398

  

Age

0.367

  

Etiology of cirrhosis

0.245

  

Portal vein tumor thrombus

0.048

0.016

0.422(0.209,0.853)

BCLC staging

0.035

0.311

1.089(0.542,2.189)

Pre-treatment ECOG

0.064

0.309

0.712(0.388,1.309)

AFP

0.251

  

Pre-treatment liver function

0.875

  

Pre-treatment bilirubin

0.085

0.613

0.995(0.956,1.036)

Pretreatment AST

0.162

  

Pretreatment ALT

0.803

  

Pretreatment WBC

0.507

  

Pretreatment RBC

0.398

  

Pretreatment PLT

0.071

0.274

0.622(0.339,1.142)

Back to article page